pharmaphorum December 14, 2023
The Biden administration has generated a list of 48 drugs whose prices were raised faster than inflation in the last quarter of this year and may be subject to the mandatory Medicare rebate programme in the US.
The products all come under Medicare Part B, which covers drugs administered to older patients in physicians’ offices or hospital outpatient departments, and it is claimed that the rebate payments will save patients out-of-pocket costs of between $1 and $2,786 per average dose.
“Starting in January, some Medicare beneficiaries who take these 48 prescription drugs – including drugs used to treat cancer and fight infections – will have lower coinsurance than what they would have paid otherwise,” said the White House in a...
Today's Sponsors
Today's Sponsor